[A21-69] Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V
Last updated 19.11.2021
Project no.:
A21-69
Commission:
Commission awarded on 21.05.2021 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 2.0 of the dossier Assessment replaces version 1.0 published on 2021-09-01.
Federal Joint Committee (G-BA)
2021-11-19 A G-BA decision was published.